Sugi Predict

Sugi Predict / Compounds / SCHEMBL8264388

SCHEMBL8264388

SCHEMBL8264388

O=C(O)C[C@H](NC(=O)OCc1ccccc1)C(=O)N1CCC[C@H]1C(=O)c1nc2ccccc2s1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ACE P12821 2/20 0.47
▸ CASP1 P29466 7/20 0.45
▸ KMT2A Q03164 1/20 0.44
▸ ITGB3 P05106 2/20 0.44
▸ ITGAV P06756 2/20 0.44
▸ PREP P48147 2/20 0.43
▸ REN P00797 1/20 0.43
▸ CASP3 P42574 1/20 0.43
▸ CASP2 P42575 1/20 0.43
▸ CASP4 P49662 1/20 0.43
▸ CASP5 P51878 1/20 0.43
▸ CASP7 P55210 1/20 0.43
▸ CASP9 P55211 1/20 0.43
▸ CASP8 Q14790 1/20 0.43
▸ CASP10 Q92851 1/20 0.43
▸ DPP4 P27487 1/20 0.43
▸ DPP8 Q6V1X1 1/20 0.43
▸ HDAC3 O15379 1/20 0.43
▸ HDAC4 P56524 1/20 0.43
▸ HDAC1 Q13547 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8230028 0.93 ACE (0.54) ACEITGB3ITGAVPREPREN
SCHEMBL13475725 0.93 ACE (0.54) ACEITGB3ITGAVPREPREN
SCHEMBL1443345 0.93 ACE (0.54) ACEITGB3ITGAVPREPREN
SCHEMBL13475726 0.88 PREP (0.57) ACECASP1ITGB3ITGAVPREP
SCHEMBL13409456 0.88 PREP (0.57) ACECASP1ITGB3ITGAVPREP
SCHEMBL8263227 0.88 DPP4 (0.58) ACEDPP4DPP8HDAC3HDAC4
SCHEMBL13409461 0.85 DPP4 (0.46) ACEDPP4DPP8HDAC3HDAC4
SCHEMBL13409464 0.83 F2 (0.46) ACERENF2ACE2
SCHEMBL8079479 0.83 PREP (0.55) KMT2APREP
SCHEMBL8263228 0.81 ACE (0.55) ACEKMT2AF2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100099721-A1 NOVEL COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS PROBIODRUG AG (DE) 2010-04-22 — — US disclosed
US-20100099721-A1 NOVEL COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS PROBIODRUG AG (DE) 2010-04-22 — — US disclosed
US-7667044-B2 treating nervous system diorders such as Alzheimer's disease, Down Syndrome, Parkinson disease and Huntington chorea by administering inhibitors of prolyl endopeptidases PROBIODRUG AG (DE) 2010-02-23 — — US disclosed
US-7667044-B2 treating nervous system diorders such as Alzheimer's disease, Down Syndrome, Parkinson disease and Huntington chorea by administering inhibitors of prolyl endopeptidases PROBIODRUG AG (DE) 2010-02-23 — — US disclosed
WO-2006058720-A2 NOVEL COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS PROBIODRUG AG (DE) 2006-06-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100099721-A1 NOVEL COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS PREP, BACE1, BCHE ACE 147/4885CASP1 1270/4885KMT2A 916/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.